Shares in GSK fell around 9% this morning after ... of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial. Judge Vivian Medinilla of Delaware Superior Court issued an ...
GSK and other pharma companies that have sold ranitidine products over the years have so far been fairly successful in fending off the litigation, with wins in ... for a trial court judge to ...
who did not know that GSK had for decades concealed an internal study that implicated GSK's liability to Zantac users. When the true details entered the market, the lawsuit claims that investors ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Defendants represented to investors that GSK removed Zantac from the market “[b]ased on information available at the time and correspondence with regulators,” and that GSK was “continuing ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
Companies can also be hit with expensive litigation (GSK last year paid £1.8bn to settle legal cases over its Zantac heartburn treatment). But on balance, things are looking sunny for GSK right now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback